Literature DB >> 25359859

Prospective association of polycystic ovary syndrome with coronary artery calcification and carotid-intima-media thickness: the Coronary Artery Risk Development in Young Adults Women's study.

Ronit Calderon-Margalit1, David Siscovick2, Sharon S Merkin2, Erica Wang2, Martha L Daviglus2, Pamela J Schreiner2, Barbara Sternfeld2, O Dale Williams2, Cora E Lewis2, Ricardo Azziz2, Stephen M Schwartz2, Melissa F Wellons2.   

Abstract

OBJECTIVE: To study the independent associations of polycystic ovary syndrome (PCOS), and its 2 components, hyperandrogenism and anovulation, with coronary artery calcification (CAC) and carotid artery intima-media thickness (IMT). APPROACH AND
RESULTS: At the year 20 of the Coronary Artery Risk Development in Young Adults (CARDIA) study, a population-based multicenter cohort of young adults, women (mean age, 45 years) with information on menses and hirsutism in their twenties were assessed for CAC (n=982) and IMT (n=988). We defined PCOS as women who had both irregular menses and hyperandrogenism (n=55); isolated oligomenorrhea (n=103) as women who only had irregular menses; and isolated hyperandrogenism (n=156) as women who had either hirsutism or increased testosterone levels. Logistic regressions and general linear models were used to estimate the associations between components of PCOS and subclinical CVD. The prevalence of CAC was 10.3% overall. Women with PCOS had a multivariable adjusted odds ratio of 2.70 (95% confidence interval, 1.31-5.60) for CAC. Women with either isolated oligomenorrhea or isolated hyperandrogenism had no increased risk of CAC when compared with unexposed women. Women with PCOS had significantly increased bulb and internal carotid-IMT measurements; however, no significant differences were noted in bulb or internal carotid artery IMT among women with either isolated oligomenorrhea or isolated hyperandrogenism when compared with unexposed women. There were no differences in common carotid-IMT among the 4 study groups.
CONCLUSIONS: In this study, women with PCOS, manifested as both anovulation and hyperandrogenism, but not women with one of these manifestations alone, were at increased risk for the development of subclinical CVD.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  carotid intima media thickness; cohort studies; coronary atherosclerosis; electron beam computed tomography; polycystic ovary syndrome; risk

Mesh:

Year:  2014        PMID: 25359859     DOI: 10.1161/ATVBAHA.114.304136

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  27 in total

Review 1.  Sex differences in vascular physiology and pathophysiology: estrogen and androgen signaling in health and disease.

Authors:  Austin C Boese; Seong C Kim; Ke-Jie Yin; Jean-Pyo Lee; Milton H Hamblin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

2.  Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers.

Authors:  Sonali S Patel; Uyen Truong; Martina King; Annie Ferland; Kerrie L Moreau; Jennifer Dorosz; John E Hokanson; Hong Wang; Gregory L Kinney; David M Maahs; Robert H Eckel; Kristen J Nadeau; Melanie Cree-Green
Journal:  Vasc Med       Date:  2017-01-17       Impact factor: 3.239

Review 3.  Cardiometabolic Risk in PCOS: More than a Reproductive Disorder.

Authors:  Laura C Torchen
Journal:  Curr Diab Rep       Date:  2017-11-11       Impact factor: 4.810

4.  Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program.

Authors:  Catherine Kim; Vanita R Aroda; Ronald B Goldberg; Naji Younes; Sharon L Edelstein; MaryLou Carrion-Petersen; David A Ehrmann
Journal:  J Clin Endocrinol Metab       Date:  2018-02-01       Impact factor: 5.958

Review 5.  Pregnancy and Reproductive Risk Factors for Cardiovascular Disease in Women.

Authors:  Anna C O'Kelly; Erin D Michos; Chrisandra L Shufelt; Jane V Vermunt; Margo B Minissian; Odayme Quesada; Graeme N Smith; Janet W Rich-Edwards; Vesna D Garovic; Samar R El Khoudary; Michael C Honigberg
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

6.  A Systematic Review and Meta-Analysis of the Association Between Polycystic Ovary Syndrome and Coronary Artery Calcification.

Authors:  Olatokunbo Osibogun; Oluseye Ogunmoroti; Olamide B Kolade; Allison G Hays; Victor Okunrintemi; Anum S Minhas; Martha Gulati; Erin D Michos
Journal:  J Womens Health (Larchmt)       Date:  2022-05-16       Impact factor: 3.017

7.  Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome.

Authors:  Ling Gao; Jia-Tian Cao; Yan Liang; Yi-Chao Zhao; Xian-Hua Lin; Xiao-Cui Li; Ya-Jing Tan; Jing-Yi Li; Cheng-Liang Zhou; Hai-Yan Xu; Jian-Zhong Sheng; He-Feng Huang
Journal:  Endocrine       Date:  2015-11-17       Impact factor: 3.633

8.  Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome.

Authors:  C Noel Bairey Merz; Leslee J Shaw; Ricardo Azziz; Frank Z Stanczyk; George Sopko; Glenn D Braunstein; Sheryl F Kelsey; Kevin E Kip; Rhonda M Cooper-DeHoff; B Delia Johnson; Viola Vaccarino; Steven E Reis; Vera Bittner; T Keta Hodgson; William Rogers; Carl J Pepine
Journal:  J Womens Health (Larchmt)       Date:  2016-06-06       Impact factor: 2.681

9.  Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists.

Authors:  Angela H E M Maas; Giuseppe Rosano; Renata Cifkova; Alaide Chieffo; Dorenda van Dijken; Haitham Hamoda; Vijay Kunadian; Ellen Laan; Irene Lambrinoudaki; Kate Maclaran; Nick Panay; John C Stevenson; Mick van Trotsenburg; Peter Collins
Journal:  Eur Heart J       Date:  2021-03-07       Impact factor: 29.983

10.  Polycystic Ovary Syndrome (PCOS) Transition at Menopause.

Authors:  Duru Shah; Sabahat Rasool
Journal:  J Midlife Health       Date:  2021-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.